Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Informationsteknik |
| Industri | Programvara |
Helsinki, Finland - August 13, 2025 - Nordhealth is increasing its investments in product development for AI and DACH localisation in 2025:
1. Accelerating the localisation of flagship veterinary practice management software, Provet Cloud, into DACH markets: The company believes that the market for veterinary enterprise clients in DACH is increasingly compelling. Additionally, the company believes that the evolving differences in service quality and profitability, between Provet Cloud, and Nordhealth's acquired DACH legacy platform, Vetera, justify accelerating the groundwork to migrate Vetera clients onto Provet Cloud.
2. Development of AI features across both of Nordhealth's Veterinary and Therapy business units: Based on the early results of our AI-scribe trials in Therapy, and an enhanced AI-roadmap across both business units, Nordhealth believes the return on investment of AI development will justify the increased expenditure.
The total increases in product development expenditure from 2024 to 2025 are expected to be around €3.1M.
As a result of these investments, Nordhealth is revising its 2025 target for `Adj. EBITDA - CAPEX' from `between -€2.0M and +€2.0M', to `between -€4.0M and -€2.0M'.
Nordhealth's growth guidance remains unchanged: The company continues to anticipate between 12% and 17% growth in `Vet + Therapy recurring revenue' in 2025 compared to 2024, calculated at a constant currency rate as of December 31, 2024.
Cash and cash equivalents in the Nordhealth Group as at 30 June 2025 (including amounts invested in money market funds), is €20.5M.
A full update on the business and its growth initiatives will be provided in the Q2 Investor Presentation on Aug 19, 2025.
For further information, please contact:
Charles MacBain, Group CEO, charles.macbain@nordhealth.com, +44 75 3903 2200
Alexander Cram, Group CFO, alexander.cram@nordhealth.com, +32 470 69 30 20
This stock announcement includes inside information pursuant to article 7 of the EU Market Abuse Regulation and was published in accordance with section 5-12 of the Norwegian Securities Trading Act by Alexander Cram, Group CFO on the date and time indicated above.